Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study
2020
Bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) was Food and Drug Administration approved in February 2018. The paucity of real-world data prompted this retrospective, observational evaluation of discontinuation rates, adverse effects, and virologic control. In a Southern US, predominantly African American overweight population, we found optimal virologic control and low discontinuation rates, with 4% discontinuing BIC/FTC/TAF due to rash, low platelets, loss of appetite, and insomnia.
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
5
References
2
Citations
NaN
KQI